Thrombosis is the interruption of blood flow by a clot in the blood vessels. Retinal Artery Thrombosis, also known as a Retinal Vein Occlusion, is when the arteries that transport blood to the retina become blocked. Retinal Artery Thrombosis is most commonly caused by atherosclerosis, which is the thickening of the arteries. People with diabetes, high blood pressure, and some eye problems have an increased risk for Retinal Artery Thrombosis. Symptoms of Retinal Vein Thrombosis are blurring or loss of vision and vision improves after treatment, but rarely does it come back completely. Retinal Artery Thrombosis is treated with anti-vessel growing drugs to prevent abnormal blood vessel growth.
Retinal Artery Thrombosis Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Retinal Artery Thrombosis below!
For more information on how to use Laverne, please read the How to Guide.
We have 530 products for the study of Retinal Artery Thrombosis that can be applied to Chromatin Immunoprecipitation, Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Retinal Artery Thrombosis is also known as Thrombosis Of Retinal Artery.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.